Q2 FY26 results: revenue up 12% YoY, PAT drops about 49% on margin pressure

Revenue Growth 20pctEbitda Margin CompressionNegative Operating CashflowResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹85.49

prior close

₹84.23

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-4.3% vs market

Pharmaceuticals peers, median of 155sector-0.1%-4.5% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 4.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-3.4

15m

-2.7

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7-0.4-4.3-0.1-4.5

Next day

-5.0-0.6-4.3-0.7-4.3

-4.2+0.3-4.5+0.4-4.6

-4.0+0.2-4.2+0.0-4.0

-4.8+0.1-5.0+0.4-5.2

-5.3+0.7-6.0+0.3-5.6

-5.5-0.3-5.2-0.7-4.8

15d

-6.4-2.0-4.4-1.4-5.0

-6.6-5.7-0.9-3.6-3.0

-10.1-7.8-2.3-6.2-3.9

-2.2-4.6+2.5-6.9+4.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 revenue from operations at Rs 18,588 lakhs, up around 12 percent YoY. H1 revenue rose about 22.5 percent to Rs 37,236 lakhs. However PAT fell sharply: Q2 PAT Rs 761 lakhs against Rs 1,504 lakhs last year, H1 PAT Rs 1,591 lakhs against Rs 2,455 lakhs. EBITDA margin compressed to 7.13 percent from 11.38 percent a year ago. Operating cash flow turned negative at minus Rs 2,680 lakhs in H1. Board also adopted revised governance policies. One-for-one bonus shares were allotted in July 2025.

Likely market impact

Mixed - topline growth intact but steep profit decline, weak operating cash flow and bonus-related cost pressures may weigh on sentiment.